WO2005005614A3 - Combined b-cell and t-cell epitopes on vlp for improved vaccines - Google Patents

Combined b-cell and t-cell epitopes on vlp for improved vaccines Download PDF

Info

Publication number
WO2005005614A3
WO2005005614A3 PCT/US2004/021381 US2004021381W WO2005005614A3 WO 2005005614 A3 WO2005005614 A3 WO 2005005614A3 US 2004021381 W US2004021381 W US 2004021381W WO 2005005614 A3 WO2005005614 A3 WO 2005005614A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
vlp
epitopes
combined
terminus
Prior art date
Application number
PCT/US2004/021381
Other languages
French (fr)
Other versions
WO2005005614A2 (en
Inventor
Vsevolod Katritch
Robert J Deans
Ole Lund
Soeren Brunak
Original Assignee
Pecos Labs Inc
Vsevolod Katritch
Robert J Deans
Ole Lund
Soeren Brunak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pecos Labs Inc, Vsevolod Katritch, Robert J Deans, Ole Lund, Soeren Brunak filed Critical Pecos Labs Inc
Publication of WO2005005614A2 publication Critical patent/WO2005005614A2/en
Publication of WO2005005614A3 publication Critical patent/WO2005005614A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition is described to induce simultaneous humoral (B-cell) and cell-mediated (CTL) immune responses against single or multiple antigens of a pathogenic virus bacteria, or cancer cell. Multiple B-cell and T-cell epitopes are identified in the pathogen proteome by computational and experimental techniques, and genetically inserted into a virus-like particle (VLP). Different insertion sites for B-cell and T-cell epitopes can be chosen at N-terminus, C-terminus or within the sequence of the VLP protein for optimal presentation of the epitopes.
PCT/US2004/021381 2003-07-03 2004-07-06 Combined b-cell and t-cell epitopes on vlp for improved vaccines WO2005005614A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48430703P 2003-07-03 2003-07-03
US60/484,307 2003-07-03

Publications (2)

Publication Number Publication Date
WO2005005614A2 WO2005005614A2 (en) 2005-01-20
WO2005005614A3 true WO2005005614A3 (en) 2005-12-01

Family

ID=34062039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021381 WO2005005614A2 (en) 2003-07-03 2004-07-06 Combined b-cell and t-cell epitopes on vlp for improved vaccines

Country Status (1)

Country Link
WO (1) WO2005005614A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006309286A1 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
WO2008109686A2 (en) * 2007-03-05 2008-09-12 Neurok Pharma Llc Non- infectious recombinant virus-like particles and their pharmaceutical applications
WO2014116730A2 (en) * 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719978B2 (en) * 1998-10-21 2004-04-13 The United States Of America As Represented By The Department Of Health And Human Services Virus-like particles for the induction of autoantibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719978B2 (en) * 1998-10-21 2004-04-13 The United States Of America As Represented By The Department Of Health And Human Services Virus-like particles for the induction of autoantibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHACKERIAN B.: "Induction of Autoantibodies to Mouse CCR5 with Recombinant Papillomavirus Particles", PROC. NATL. ACAD. SCI. USA, vol. 96, March 1999 (1999-03-01), pages 2373 - 2378, XP002133522 *

Also Published As

Publication number Publication date
WO2005005614A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2003024481A3 (en) Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
MXPA05009289A (en) Melan-a peptide analogue-virus-like-particle conjugates.
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
NO20072253L (en) Improved vaccines
WO2001014416A3 (en) Synthetic papillomavirus genes optimized for expression in human cells
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
IL134341A0 (en) Compositions for inducing an immune response containing an hpv protein antigen
HUP0004327A1 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
WO2002070006A3 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
WO2004044176A3 (en) Adenoviral vector vaccine
EA200701440A1 (en) COMPOSITIONS FOR IMMUNIZATION AGAINST MYCOBACTERIA
NZ589755A (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
WO2004032860A3 (en) Hiv vaccine formulations
ZA200706389B (en) Compositions for immunizing against mycobacterium
WO2005076975A3 (en) Complexed polypeptide and adjuvant for improved vaccines
WO2005005614A3 (en) Combined b-cell and t-cell epitopes on vlp for improved vaccines
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
JP2004503217A5 (en)
WO2002024730A3 (en) Transduction of dendritic cells using adenoviral vectors
EP2368572A3 (en) Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
AU2003229435A1 (en) Pathogen vaccines and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase